We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Can India become a biosimilar powerhouse?
News

Can India become a biosimilar powerhouse?

Can India become a biosimilar powerhouse?
News

Can India become a biosimilar powerhouse?

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Can India become a biosimilar powerhouse?"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alistair Sinclair, healthcare analyst at Datamonitor, comments: “The domestic market for biosimilars in India is limited by low levels of health insurance and therefore poor access to biologic drugs; however given the high level of branded-generic loyalty of the emerging middle class, this could act as a driver of biosimilar uptake.

“Due to the fact that many copycat biologics are already available in India and often approved as new drugs rather than biosimilars, it is difficult to quantify biosimilar sales in the emerging markets. Nevertheless, estimates in India range from as low as $20m and as high as $200m. This could be expected to grow to $580m by 2012.”

Whilst the domestic market shows potential, many Indian biosimilar manufacturers are also looking to expand globally.

Alistair explains: “The developed pharma markets may be difficult to access alone due to the complex and expensive clinical trials and registration process. However,  licensing agreements with multinational companies,  such as the recent deal between Biocon and Pfizer, can facilitate access to these markets.”

Want to find out more on the Indian Pharmaceutical Market? Click here for Datamonitor’s overview of the Indian pharmaceutical market including socioeconomic trends, regulatory issues, market sizing, expiry analysis and drug infrastructure analysis.

Advertisement